IngenioRx quarterly Drug and Biologic Pipeline Update available

IngenioRx closely monitors drugs, biologics, and gene therapies in development. Our Q1 2021 IngenioRx Drug and Biologic Pipeline Update highlights significant upcoming FDA approvals. Share it with your clients to make them aware of potential new options for their employees.

Topics include:

A safer alternative for certain autoimmune disorder patients on high-dose corticosteroids
A first-of-its-kind gene therapy for a rare blood disorder
A therapy for a rare complication of stem cell transplants
Significant therapies that could gain FDA approval in the next several months
New products in the pipeline to treat eczema
Unique insight into biosimilars and other market trends

IngenioRx offers this free publication to improve community health, reduce waste, lower total cost of care, and estimate future costs.

View and download the quarterly update to learn more.

SpecialtyRx Savings Navigator cost management solution coming in June

SpecialtyRx Savings Navigator will be available this June for new or renewing ASO Large Groups and National accounts with 500 or more subscribers. It’s provided by our pharmacy benefit manager, CarelonRx. SpecialtyRx Savings Navigator offers comprehensive specialty drug cost management that helps...

We’re promoting our value to groups still with Humana

We will continue our Large and Small Group marketing campaign for employers still with Humana. It will continue through April and, tentatively, through September. If one of your clients responds, we will connect with you to keep you involved. Our messaging will showcase Anthem’s value story and ...

IngenioRx quarterly Drug and Biologic Pipeline Update available

More Articles

SpecialtyRx Savings Navigator cost management solution coming in June

We’re promoting our value to groups still with Humana